Drugs / Pittsburgh compound B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04542603 | Jun 2025 → Aug 2026 | ovarian cancer | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pittsburgh compound B | “well-characterized small molecule PET(Positron Emission Tomography) tracer, 11C-labeled Pittsburgh compound B (PiB)” NCT04542603 ↗ |
| Known as | PiB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04542603 ↗ |
| Modality | Diagnostic / imaging agent | “well-characterized small molecule PET(Positron Emission Tomography) tracer, 11C-labeled Pittsburgh compound B (PiB)” NCT04542603 ↗ |